Turpaz Industries (TRPZ) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
3 Nov, 2026Executive summary
H1 2026 revenue was $173.870M, up 40.5% YoY with 8.1% organic growth; Q2 revenue was $90.229M, up 42.3% with 7.3% organic growth.
H1 Adjusted EBITDA was $40.008M at a 23.0% margin; Q2 Adjusted EBITDA was $20.619M at a 22.9% margin.
Acquisition-led expansion and organic growth supported record results; eight acquisitions were completed since the start of 2025.
Financial highlights
H1 gross profit was $72.468M, up 50.2%, with a 41.7% margin; Q2 gross profit was $37.439M, up 51.5%, with a 41.5% margin.
H1 net income rose 80.9% to $19.233M; non-GAAP net income was $23.428M, up 52.7%.
Q2 net income rose 56.4% to $8.168M; non-GAAP net profit was $11.7M, up 56.9%.
H1 operating cash flow was $15.779M vs. $13.134M; Q2 cash flow was $10.0M, up 79.2%.
H1 operating income was $24.974M vs. $19.556M; Q2 operating income was $12.100M, up 22.0%.
Outlook and guidance
Strategic goal is to double sales every four years or less; annualized sales run rate, including Phoenix and Romessence as if consolidated from Q2 start, was estimated at ~$380M.
Growth plans emphasize organic expansion, synergies, cross-selling, strategic M&A, partnerships and an active acquisition pipeline.
Phoenix and Klabin-Turpaz US consolidation is expected to generate $2M in synergies over coming quarters; acquired fragrance businesses are also expected to improve profitability.
New specialty-ingredient molecules and production lines are expected to support improved sales and profitability as ramp-up progresses.
Latest events from Turpaz Industries
- Record Q1 growth was led by Taste and acquisitions, while Specialty Fine Ingredients weakened.TRPZ
Q1 2024 - Acquisitions and Taste/Scent growth lifted record results despite Specialty Fine Ingredients weakness.TRPZ
Q2 2024 - Acquisition-led growth lifted sales and adjusted EBITDA as Specialty Fine Ingredients weakened.TRPZ
Q3 2024 - FY24 sales rose 48.4%, with adjusted EBITDA up 54.8%.TRPZ
Q4 2024 - Record Q1 sales of $60.4M and adjusted EBITDA of $13.6M reflected organic growth and acquisitions.TRPZ
Q1 2025 - Q2 sales grew 35.6%, with 14.2% organic growth and a 23.1% adjusted EBITDA margin.TRPZ
Q2 2025 - Q3 sales rose 57.4% as organic growth and acquisitions lifted adjusted EBITDA 55.1%.TRPZ
Q3 2025 - Revenue rose 45.6% in 2025 as adjusted EBITDA margin reached 23.1%.TRPZ
Q4 2025 - Q1 revenue rose 38.6%; Phoenix and Romessence lifted the sales run rate to $380m.TRPZ
Q1 2026